Media Coverage

Media articles featuring INFORMS members in the news.

Most Recent Media Coverage

Topic
NC's Focus on Data Has Helped State Shrink the Racial Vaccine Gap - Somewhat

NC's Focus on Data Has Helped State Shrink the Racial Vaccine Gap - Somewhat

Independent Tribune, March 6, 2021

North Carolina is among the best-performing U.S. states when it comes to distributing vaccines evenly among Black and white residents. That’s partly because the state is by far the best at collecting demographic data. About 11% of North Carolina’s Black population has received at least one shot, compared with 17% of the state’s white residents, the Bloomberg Vaccine Tracker shows. That puts North Carolina in fourth place for the smallest spread between the two groups among states with the most comprehensive data sets. Other states might be doing as well or better than North Carolina in terms of equality, though huge numbers of incomplete records obscure the national picture.

Backlash Against Johnson & Johnson's COVID-19 Vaccine is Real and Risky - Here's How to Make Its Rollout A Success

Backlash Against Johnson & Johnson's COVID-19 Vaccine is Real and Risky - Here's How to Make Its Rollout A Success

The Conversation, March 5, 2021

More than 50 million Americans have received at least one dose of either the Pfizer or Moderna COVID-19 vaccine. So far, Americans have been largely brand-agnostic, but that’s about to change as a new vaccine rolls out. The Johnson & Johnson vaccine has been hailed as a game changer. It requires only a single dose rather than two doses spaced weeks apart, and it does not need freezer storage, making it a natural fit for hard-to-reach rural areas and underserved communities with limited access to health care and storage facilities. But while many people are excited about the prospects of only one shot, the new vaccine is also getting backlash. Part of that is coming from lack of clarity about the vaccines’ efficacy numbers, and part of it is more nuanced. 

Backlash Against Johnson & Johnson's COVID-19 Vaccine is Real and Risky - Here's How to Make Its Rollout A Success

Backlash Against Johnson & Johnson's COVID-19 Vaccine is Real and Risky - Here's How to Make Its Rollout A Success

Times Union, March 5, 2021

More than 50 million Americans have received at least one dose of either the Pfizer or Moderna COVID-19 vaccine. So far, Americans have been largely brand-agnostic, but that’s about to change as a new vaccine rolls out. The Johnson & Johnson vaccine has been hailed as a game changer. It requires only a single dose rather than two doses spaced weeks apart, and it does not need freezer storage, making it a natural fit for hard-to-reach rural areas and underserved communities with limited access to health care and storage facilities. But while many people are excited about the prospects of only one shot, the new vaccine is also getting backlash. Part of that is coming from lack of clarity about the vaccines’ efficacy numbers, and part of it is more nuanced.

Backlash Against Johnson & Johnson's COVID-19 Vaccine is Real and Risky - Here's How to Make Its Rollout A Success

Backlash Against Johnson & Johnson's COVID-19 Vaccine is Real and Risky - Here's How to Make Its Rollout A Success

My Journal Courier, March 5, 2021

More than 50 million Americans have received at least one dose of either the Pfizer or Moderna COVID-19 vaccine. So far, Americans have been largely brand-agnostic, but that’s about to change as a new vaccine rolls out. The Johnson & Johnson vaccine has been hailed as a game changer. It requires only a single dose rather than two doses spaced weeks apart, and it does not need freezer storage, making it a natural fit for hard-to-reach rural areas and underserved communities with limited access to health care and storage facilities. But while many people are excited about the prospects of only one shot, the new vaccine is also getting backlash. Part of that is coming from lack of clarity about the vaccines’ efficacy numbers, and part of it is more nuanced.

The Secret Behind North Dakota’s Speedy Vaccine Rollout

The Secret Behind North Dakota’s Speedy Vaccine Rollout

Wired, March 4, 2021

The pharmacy in Hankinson, North Dakota, a town of about 900 people at the state’s extreme southeastern tip, has been in operation since 1897. The town was a decade old by then and had quickly swelled with settlers enticed by ads for good farmland along the railroad. A pharmacy was one of those signs of a town’s arrival; a knowledgeable druggist was essential. This remained true through the years, even though it turned out that the region’s population had already peaked and was slowly dwindling, as it still is. The earliest owners of Hankinson Drug had kept a stock of jewelry as well as pharmaceuticals, and both traditions remain alive with the current proprietors. In recent years, their pharmacy has been the only one in the county outside Wahpeton, a bigger town 30 minutes away on the Minnesota border.

Media Contact

Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
[email protected]
443-757-3578

Resoundingly Human Podcast

An audio journey of how data and analytics save lives, save money and solve problems.

Artificial Intelligence

Study finds ChatGPT mirrors human decision biases in half the tests

Study finds ChatGPT mirrors human decision biases in half the tests

Celebrity Gig, April 2, 2025

Can we really trust AI to make better decisions than humans? A new study says … not always. Researchers have discovered that OpenAI’s ChatGPT, one of the most advanced and popular AI models, makes the same kinds of decision-making mistakes as humans in some situations—showing biases like overconfidence of hot-hand (gambler’s) fallacy—yet acting inhuman in others (e.g., not suffering from base-rate neglect or sunk cost fallacies).

Why 23andMe’s Genetic Data Could Be a ‘Gold Mine’ for AI Companies

Why 23andMe’s Genetic Data Could Be a ‘Gold Mine’ for AI Companies

TIME, March 26, 2025

The genetic testing company 23andMe, which holds the genetic data of 15 million people, declared bankruptcy on Sunday night after years of financial struggles. This means that all of the extremely personal user data could be up for sale—and that vast trove of genetic data could draw interest from AI companies looking to train their data sets, experts say.

Healthcare

Want to reduce the cost of healthcare? Start with our billing practices.

Want to reduce the cost of healthcare? Start with our billing practices.

The Hill, March 11, 2025

Robert F. Kennedy Jr., as the new secretary of Health and Human Services, is the nation’s de facto healthcare czar. He will have influence over numerous highly visible agencies, including the Centers for Disease Control and Prevention, the National Institutes of Health and the Food and Drug Administration, among others. Given that healthcare is something that touches everyone’s life, his footprint of influence will be expansive. 

We all benefit from and are hurt by health insurance claim denials

We all benefit from and are hurt by health insurance claim denials

Atlanta Journal Constitution, January 23, 2025

Health insurance has become necessary, with large and unpredictable health care costs always looming before each of us. Unfortunately, the majority of people have experienced problems when using their health insurance to pay for their medical care. Health insurance serves as the buffer between patients and the medical care system, using population pooling to mitigate the risk exposure on any one individual.

Supply Chain

LM Podcast Series: Looking at the state of the supply chain with Rob Handfield

LM Podcast Series: Looking at the state of the supply chain with Rob Handfield

Logistics Management/, April 22, 2025

During this podcast Handfield addressed various topics, including: the current state of the supply chain; steps and actions shippers should consider related to tariffs; how the supply chain is viewed; the need for supply chain resiliency; and supply chain risk mangement planning, among others. 

Tariff fight continues between U.S. and China

Tariff fight continues between U.S. and China

FOX News, April 18, 2025

Oklahoma State University's Sunderesh Heragu joins LiveNOW's Austin Westfall to discuss the evolving economic landscape after President Trump implemented tariffs on some of our biggest trade partners. Most tariffs have been halted for now -- but not with China. Beijing and the White House have levied steep tariffs on each other. Trump announced that tariffs on China would reach 145 percent. In response, China imposed 125 percent tariffs on U.S.-imported goods.

Climate